柔红霉素个体差异的遗传药理学研究进展

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (10): 1182-1185.

柔红霉素个体差异的遗传药理学研究进展

何晖^1,2, 周宏灏¹, 刘昭前¹

¹中南大学临床药理研究所,湖南省遗传药理学重点实验室,长沙 410078,湖南;
²中国医科大学本溪中心医院,本溪 117000,辽宁

收稿日期:2012-09-24 修回日期:2013-06-20 出版日期:2013-10-26 发布日期:2013-09-30
通讯作者: 刘昭前, 男,博士,教授,博士生导师,研究方向:遗传药理学与药物基因组学。Tel: 0731-84805380 E-mail: liuzhaoqian63@126.com
作者简介:何晖,男,在站博士后,研究方向:遗传药理学与药物基因组学。Tel: 0731-84805380 E-mail: xykhh@yahoo.com.cn
基金资助:
国家高技术研究发展计划(863计划)(2012AA02A517);国家自然科学基金(81173129);湖南省自然科学创新群体基金(12JJ7006);辽宁省博士科研启动基金(20111111);辽宁省财政厅省科技专项经费辽财企[2008]934号)

Research progress on pharmacogenomics of daunorubicin individual differences

HE Hui^1,2, ZHOU Hong-hao¹, LIU Zhao-qian¹

¹Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Genetic Pharmacology, Changsha 410078, Hunan, China;
²Benxi Central Hospital of China Medical University, Benxi 117000,Liaoning,China

Received:2012-09-24 Revised:2013-06-20 Online:2013-10-26 Published:2013-09-30

摘要/Abstract

摘要： 柔红霉素是临床上常用的抗白血病药物,疗效显著但是存在明显的个体差异。如何更多了解可能引起柔红霉素耐药的因素,从而提高柔红霉素的疗效,降低耐药,及减少药物的副反应,是目前临床工作者关心的问题。本文综述了影响柔红霉素药代动力学和药效学的遗传因素,旨在为柔红霉素临床个体化给药提供一定的参考依据。

关键词: 柔红霉素, 基因多态性, 白血病

Abstract: Daunorubicin is a clinical anti-leukemia drug.The effect is significant but there are significant individual differences. How to learn more about the factors that may cause daunorubicin resistant,thereby improving the efficacy of daunomycin, reducing resistance, and reducing the side effects of the drug, is a concern of clinical worker. This article reviews the genetic factors that affect daunorubicin pharmacokinetics and pharmacodynamics and provides some reference for daunorubicin individualized clinical administration .

Key words: Daunorubicin, Gene polymorphism, Leukemia

中图分类号:

R969

何晖, 周宏灏, 刘昭前. 柔红霉素个体差异的遗传药理学研究进展[J]. 中国临床药理学与治疗学, 2013, 18(10): 1182-1185.

HE Hui, ZHOU Hong-hao, LIU Zhao-qian. Research progress on pharmacogenomics of daunorubicin individual differences[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1182-1185.

参考文献

[1] Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia[J]. Pharmacogenomics, 2009,10(11): 1839-1851.
[2] O'Donnell MR, Brown PA, Aoun P, et al. Acute myeloid leukemia[J]. J Natl Compr Canc Netw,2012, 10(8):984-1021.
[3] Alvarnas JC, Abboud CN, Altman J, et al. Acute lymphoblastic leukemia[J]. J Natl Compr Canc Netw, 2012,10(7):858-914.
[4] Quiney C, Billard C, Faussat AM, et al. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells[J]. Leuk Lymphoma, 2007, 48(8): 1587-1599.
[5] Szuławska A, Czyz M. Molecular mechanisms of anthracyclines action[J]. Postepy Hig Med Dosw , 2006,60: 78-100.
[6] Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia[J]. Cancer Cell, 2005, 7(4): 375-386.
[7] Holleman A, Cheok MH, den Boer ML, et al.Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment[J]. N Engl J Med, 2004, 351(6): 533-542.
[8] Hodges LM, Markova SM, Chinn LW,et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)[J]. Pharmacogenet Genomics,2011, 21(3): 152-161.
[9] Dantzig, AH, Law KL, Cao J, et al. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic[J]. Curr Med Chem, 2001, 8(1): 39-50.
[10] Dey S. Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition[J]. Expert Opin Drug Deliv, 2006, 3(1): 23-35.
[11] Yin JY, Huang Q, Yang Y, et al.Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population[J]. Pharmacogenet Genomics, 2009,19(3): 206-216.
[12] Green H,Falk IJ, Lotfi K,et al.Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype[J]. Pharmacogenomics J, 2012,12(2): 111-118.
[13] Jeong H, Herskowitz I, Kroetz DL, et al. Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay[J]. PLoS Genet, 2007, 3(3): e39.
[14] Bains OS, Karkling MJ, Lubieniecka JM, et al. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism[J]. J Pharmacol Exp Ther,2012, 332(3): 755-763.
[15] Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy[J]. Cardiovasc Toxicol, 2007, 7(2): 56-60.
[16] Visscher H, Ross CJ, Rassekh SR,et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children[J]. J Clin Oncol,2012, 30(13): 1422-1428.
[17] Fan L, Goh BC, Wong CI,et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity[J]. Pharmacogenet Genomics, 2008,18(7): 621-631.
[18] Rajic V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood[J]. Leuk Lymphoma, 2009, 50(10): 1693-1698.
[19] Blanco JG, Aplenc R, Debeljak M,et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children's Oncology Group[J]. J Clin Oncol,2012, 30(13): 1415-1421.
[20] Mahlknecht U, Dransfeld CL, Bulut N, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival[J]. Leukemia, 2009, 23(10): 1929-1932.
[21] Huang RS, Duan S, Kistner EO,et al. Genetic variants contributing to daunorubicin-induced cytotoxicity[J]. Cancer Res, 2008, 68(9): 3161-3168.
[22] Amitai Y, Bhooma T, Frischer H. Glucose-6-phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes[J]. J Lab Clin Med, 1996, 127(6): 588-598.
[23] Baer-Dubowska W, Majchrzak-Celinska A,Cichocki M. Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs[J]. Pharmacol Rep,2012,63(2): 293-304.
[24] Duan S, Bleibel WK, Huang RS, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity[J]. Cancer Res, 2007, 67(11): 5425-5433.
[25] Gamazon ER Huang RS, Cox NJ, et al. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci[J]. Proc Natl Acad Sci USA,2012,107(20): 9287-9292.